Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 7/2010

01-09-2010 | Original Article

Diagnostic utility of immunohistochemical panel in various thyroid pathologies

Authors: Arturs Ozolins, Zenons Narbuts, Ilze Strumfa, Guna Volanska, Janis Gardovskis

Published in: Langenbeck's Archives of Surgery | Issue 7/2010

Login to get access

Abstract

Background

For management of thyroid nodules, distinction between benign and malignant tumours is essential. The study was performed to evaluate the diagnostic value of molecular markers in different thyroid tumours.

Materials and methods

Immunohistochemistry for CD56, HBME-1, COX-2, Ki-67, p53 and E-cadherin (E-CAD) was performed in 113 benign and 35 malignant thyroid lesions including 36 follicular adenomas (FA), 77 colloid goitres, 26 papillary thyroid carcinomas (PTC) and 9 follicular carcinomas (FC). The results were scored semiquantitatively by staining intensity (0–3 scale) and percentage of positive cells.

Results

PTC was characterised by decreased E-CAD and CD56 expression in contrast to surrounding benign thyroid tissues. HBME-1 expression was absent in benign thyroid tissues but was notably high in PTC and occasionally in FC. The expression of E-CAD and CD56 in FA was significantly higher than in the surrounding thyroid tissues. No expression of p53 was found in any group. The expression of COX-2 was low in all lesions. The proliferation activity by Ki-67 was generally low; however, it was significantly higher in cancers.

Conclusions

The panel consisting of three markers, HBME-1, E-CAD and CD56, can be recommended as an adjunct to morphology criteria. HBME-1 is found in malignant lesions only and is the most sensitive and specific single marker in PTC. Decreased expression of E-CAD and CD56 distinguishes PTC from FA and FC. Both FA and FC are characterised by high expression of E-CAD and CD56. The practical use of Ki-67 is difficult due to low values. The role of adhesion factors in thyroid malignancies may be superior in comparison with cell proliferation.
Literature
1.
Gharib H, Papini E (2007) Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin N Am 36:707–735CrossRef
2.
Topliss D (2004) Thyroid incidentaloma: the ignorant in pursuit of the impalpable. Clin Endocrinol (Oxf) 60:18–20CrossRef
3.
Hundahl SA et al (1998) A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648CrossRefPubMed
4.
Finley DJ et al (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214–3223CrossRefPubMed
5.
Liu YY et al (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158:375–384CrossRefPubMed
6.
Haugen BR, Woodmansee WW, McDermott MT (2002) Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf) 56:281–290CrossRef
7.
Bancroft JD, Gamble M (2003) Theory and practice of histological techniques, international edition. Churchill Livingstone, Edinburgh
8.
9.
Altman DG, Machin D, Bryant TN, Gardner MJ (2005) Statistics with confidence, 2nd edn. BMJ, Bristol
10.
Sheibani K et al (1992) Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 23:107–116CrossRefPubMed
11.
Saleh HA et al (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 5:9CrossRefPubMed
12.
Miettinen M, Karkkainen P (1996) Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity malignant tumours. Virchows Arch 429:213–219CrossRefPubMed
13.
Sack MJ et al (1997) HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668–674PubMed
14.
Mai KT et al (2002) Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40:133–142CrossRefPubMed
15.
Ito Y et al (2005) HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 25:179–182PubMed
16.
Papotti M et al (2005) Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541–546CrossRefPubMed
17.
Prasad ML et al (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57CrossRefPubMed
18.
Rossi ED et al (2006) Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48:795–800CrossRefPubMed
19.
Saggiorato E et al (2005) Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12:305–317CrossRefPubMed
20.
de Micco et al (2008) Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 98:818–823CrossRefPubMed
21.
Nasr MR et al (2006) Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19:1631–1637CrossRefPubMed
22.
Saleh HA et al (2009) Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 6:18CrossRefPubMed
23.
Nga ME et al (2008) HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 36:550–556CrossRefPubMed
24.
Scognamiglio T et al (2006) Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708CrossRefPubMed
25.
Mase T et al (2003) HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50:173–177CrossRefPubMed
26.
Park YJ et al (2007) Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22:621–628CrossRefPubMed
27.
Zeromski J et al (1992) Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol 89:474–478CrossRefPubMed
28.
El Demellawy D, Nasr A, Alowami S (2009) An updated review on the clinicopathologic aspects of arrhythmogenic right ventricular cardiomyopathy. Am J Forensic Med Pathol 30:78–83CrossRefPubMed
29.
El Demellawy D, Nasr A, Alowami S (2008) Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 3:5CrossRefPubMed
30.
Scarpino S et al (2007) Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 212:411–419CrossRefPubMed
31.
Hirohashi S, Kanai Y (2003) Cell adhesion system and human cancer morphogenesis. Cancer Sci 94:575–581CrossRefPubMed
32.
Eidelman S et al (1989) Expression of the cell-cell adhesion glycoprotein cell-CAM 120/80 in normal human tissues and tumors. Am J Pathol 135:101–110PubMed
33.
Brabant G et al (1993) E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 53:4987–4993PubMed
34.
Soares P et al (1997) E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 70:32–38CrossRefPubMed
35.
von Wasielewski R et al (1997) Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501–2507
36.
Graff JR et al (1998) Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063–2066PubMed
37.
Choi YL et al (2005) Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci 20:853–859CrossRefPubMed
38.
Smyth P et al (2001) Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms. Int J Surg Pathol 9:265–272CrossRefPubMed
39.
Fosslien E (2000) Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30:3–21PubMed
40.
41.
Specht MC et al (2002) Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 87:358–363CrossRefPubMed
42.
Casey MB et al (2004) Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocr Pathol 15:107–116CrossRefPubMed
43.
Cornetta AJ et al (2002) Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 112:238–242CrossRefPubMed
44.
Kim SJ et al (2003) Immunohistochemical expression of COX-2 in thyroid nodules. Korean J Intern Med 18:225–229PubMed
45.
Nose F et al (2002) Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol 117:546–551CrossRefPubMed
46.
Haynik DM, Prayson RA (2005) Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid. Arch Pathol Lab Med 129:736–741PubMed
47.
Saad AG et al (2006) Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab 91:2672–2677CrossRefPubMed
48.
Ziad el A et al (2008) Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving. Folia Histochem Cytobiol 46:461–464CrossRefPubMed
49.
Novosel I et al (2006) p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature. Lijec Vjesn 128:264–267PubMed
50.
Akslen LA, Varhaug JE (1995) Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76:1643–1654CrossRefPubMed
51.
Martinez J, Georgoff I, Levine AJ (1991) Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5:151–159CrossRefPubMed
52.
Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093CrossRefPubMed
53.
Morita N, Ikeda Y, Takami H (2008) Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg 32:2617–2622CrossRefPubMed
54.
Dobashi Y et al (1993) Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375–381CrossRefPubMed
55.
Chen BK et al (1999) Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 15:893–898PubMed
56.
Kobayashi T et al (1995) Clinicopathological findings and p53 expression of thyroid cancer in children. Surg Today 25:217–221CrossRefPubMed
Metadata
Title
Diagnostic utility of immunohistochemical panel in various thyroid pathologies
Authors
Arturs Ozolins
Zenons Narbuts
Ilze Strumfa
Guna Volanska
Janis Gardovskis
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Langenbeck's Archives of Surgery / Issue 7/2010
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-010-0690-6

Other articles of this Issue 7/2010

Langenbeck's Archives of Surgery 7/2010 Go to the issue

Mastery in Surgery

Keiichi Maruyama MD, Professor of Surgery, Tokyo

Original Article

Surgical anatomy and neurophysiology of the vagus nerve (VN) for standardised intraoperative neuromonitoring (IONM) of the inferior laryngeal nerve (ILN) during thyroidectomy

Endocrine Surgery

Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study

Endocrine Surgery

Totally endoscopic lateral parathyroidectomy: prospective evaluation of 200 patients

Original Article

Evaluation of postoperative pain after minimally invasive video-assisted and conventional thyroidectomy: results of a prospective study

Endocrine Surgery

25-hydroxy vitamin D deficiency causes parathyroid incidentalomas